At REMD, we believe that
innovative protein therapeutics and strong science can change the practice of medicine. 
We strive to create new
treatments that are effective,
safe and affordable for patients suffering from metabolic
diseases and other
serious illnesses.

REMD 477 competitively blocks glucagon
binding to the r

PNAS (2012) 109: 14393